[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.47.118. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 11, 2002

Risks of Postmenopausal Hormone Replacement

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(22):2819. doi:10.1001/jama.288.22.2819

To the Editor: The Women's Health Initiative (WHI) investigators1 stopped the estrogen plus progestin vs placebo arm of their study because they found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease (CHD), stroke, and pulmonary embolus (PE). The authors claim, based on these results, that this hormone replacement therapy (HRT) should not be recommended for primary prevention of CHD in women.

First Page Preview View Large
First page PDF preview
First page PDF preview
×